Farkas Klaudia, Pigniczki Daniella, Rutka Mariann, Szántó Kata Judit, Resál Tamás, Bor Renáta, Fábián Anna, Szepes Zoltán, Lázár György, Molnár Tamás
First Department of Medicine, University of Szeged, Szeged, Hungary.
Department of Surgery, University of Szeged, Szeged, Hungary.
Therap Adv Gastroenterol. 2021 Apr 12;14:1756284820988198. doi: 10.1177/1756284820988198. eCollection 2021.
The coronavirus disease 2019 (COVID-19) outbreak emerged in December 2019 in China and rapidly spread worldwide. Inflammatory bowel disease (IBD) patients are likely to be more susceptible to viral infections, and this is significantly influenced by the type of therapy they receive. Thus, issues specifically concerning the medical treatment of IBD patients were shortly addressed at the beginning of the pandemic. However, recently available data on the occurrence and outcome of SARS-CoV-2 infection in IBD patients does not address the concerns raised at the beginning of the pandemic. Growing evidence and the rapid changes happening over the past few weeks have helped elucidate the current situation, contribute to our understanding of the disease, and many previously raised questions could now be answered. We hereby summarise available evidence regarding viral infections and IBD, focusing on SARS-CoV infections, and we provide practical recommendations related to patient management during the COVID-19 pandemic era.
2019年12月，新型冠状病毒肺炎（COVID-19）疫情在中国爆发，并迅速在全球蔓延。炎症性肠病（IBD）患者可能更容易受到病毒感染，这受到他们所接受治疗类型的显著影响。因此，在疫情初期就迅速解决了与IBD患者医疗治疗相关的具体问题。然而，最近关于IBD患者中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的发生情况和结果的数据并未解决疫情初期提出的担忧。越来越多的证据以及过去几周迅速发生的变化有助于阐明当前形势，增进我们对该疾病的了解，许多之前提出的问题现在可以得到解答。我们在此总结关于病毒感染和IBD的现有证据，重点关注SARS-CoV感染，并提供在COVID-19大流行时代与患者管理相关的实用建议。
